SOLESENCE, INC.

Solésence, Inc. has been named Contract Manufacturing Partner of the Year in the 2026 Cosmetics Business Innovation Awards, recognizing its excellence in client satisfaction, innovation, product development, and speed-to-market. This latest accolade adds to the 12 industry awards the company has received since 2022. Solésence plans to further expand its platform by launching new technologies in skin health and healing, moving into active skin restoration with its ingredient-led, patent-backed innovations.

Solésence, Inc. announced its prototype product, Day Mode Hero Concealer SPF 50+, won three categories at the 2026 Cosmetics & Toiletries (C&T) Allē Awards: Anti-Aging, Color Cosmetics, and Compromised Skin. This achievement marks the company's fourth consecutive year of recognition at these prestigious awards. The concealer utilizes proprietary Solésence technologies, including Kleair , WHSPR , and Chromalüm , to deliver broad-spectrum SPF 50+ and skin health benefits, pushing boundaries across skincare, sun care, and makeup categories.

Solésence, Inc. announced its support for the recommendations in "A Preventable Crisis: The Case for a National UV Safety Strategy," a landmark report led by the U.K.'s All-Party Parliamentary Group (APPG) for Beauty, Hair & Wellbeing. The report, launched on May 13, highlights the U.K.'s lack of a cohesive national strategy to mitigate UV radiation, a Group 1 carcinogen, with melanoma cases projected to rise by 9% by 2038. Solésence, a member of the UV Safety Coalition, is committed to raising awareness and supporting comprehensive UV protection campaigns to drive daily protection behaviors.

Solésence, Inc. reported a decrease in total revenue for the first quarter of 2026, falling 11.4% to $12.96 million from $14.63 million in the prior year. The company also shifted from a net income of $0.08 million in Q1 2025 to a net loss of $0.77 million in Q1 2026, resulting in a basic and diluted loss per share of $0.01. Despite the revenue decline and net loss, net cash provided by operating activities significantly improved to $1.52 million, compared to a use of $7.22 million in the same period last year.

Solésence, Inc. reported its first quarter 2026 financial results, with revenue decreasing to $13.0 million from $14.6 million in the prior year period. The company recorded a net loss of $0.8 million, a shift from a net income of $0.08 million in Q1 2025. Despite the revenue decline and net loss, Solésence improved its gross margin to 26% from 23%, attributing this to disciplined execution of its "Transform and Transcend" strategic initiative focused on operational excellence. The company also highlighted the commercialization of new platform technologies and the addition of a new independent director.

Solésence, Inc. announced the commercial availability of two new proprietary platform technologies, WHSPR™ and Chromalüm™, significantly expanding its ingredient technology portfolio. WHSPR™ enables OTC-grade sensitive skin claims in previously inaccessible anhydrous formats, with clinical studies showing significant improvements in skin barrier recovery, hydration, and redness reduction. Chromalüm™ integrates broad-spectrum sun protection, including targeted high-energy visible (HEV) light protection, into color cosmetics without compromising aesthetic performance. These innovations reinforce Solésence's vertically integrated model, allowing brand partners to access differentiated product claims and expand category reach.

SOLESENCE, INC. announced the appointment of Marc James as a Class II Director to its Board of Directors, effective April 24, 2026. His term will conclude at the 2026 Annual Meeting of Shareholders. Mr. James will serve on the Audit and Finance Committee, Compensation Committee, and Nominating and Corporate Governance Committee.

Solésence, Inc. announced it will report its first quarter 2026 financial results after the market closes on Tuesday, May 12, 2026. The company will host a conference call and webcast on the same date at 7:30 a.m. CT (8:30 a.m. ET) to discuss the results. Kevin Cureton, President & Chief Executive Officer, and Laura Riffner, Chief Financial Officer, will be the speakers.

Solésence, Inc. announced the immediate appointment of Marc James as an independent director to its Board of Directors. James will also serve as a member of the Company's Audit, Compensation, and Nominating Committees. This appointment is intended to reinforce Solésence's corporate governance and enhance board expertise as the company pursues its Transform & Transcend strategic initiative and long-term growth objectives.

SOLESENCE, INC. filed an Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. This administrative filing updates the previously submitted annual report. The document confirms the company's status as a non-accelerated filer and a smaller reporting company, and indicates compliance with SEC reporting obligations.